State Street SPDR S&P Pharmaceuticals ETF
XPH
69 hedge funds and large institutions have $132M invested in State Street SPDR S&P Pharmaceuticals ETF in 2025 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 22 increasing their positions, 20 reducing their positions, and 7 closing their positions.
71% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 7
13% more capital invested
Capital invested by funds: $117M → $132M (+$15.3M)
10% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 20
6% more funds holding
Funds holding: 65 → 69 (+4)
3.37% less ownership
Funds ownership: 78.78% → 75.41% (-3.4%)
46% less call options, than puts
Call options by funds: $575K | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
+$10M |
| 2 |
LPL Financial
San Diego,
California
|
+$3.21M |
| 3 |
Cetera Investment Advisers
Schaumburg,
Illinois
|
+$2.8M |
| 4 |
Morgan Stanley
New York
|
+$2.29M |
| 5 |
CI
CX Institutional
Auburn,
Indiana
|
+$2.28M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$13.4M |
| 2 |
KWM
Kingsview Wealth Management
Grants Pass,
Oregon
|
-$9.62M |
| 3 |
Citigroup
New York
|
-$4.48M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.19M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$680K |
XPH Hedge Fund Activity: Q3 2025 in Review
69 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2025, worth a combined $132M — up 13% from $117M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new XPH positions and 7 closed out — a net gain of 5 holders — while 22 added to existing stakes and 20 trimmed.
The largest buyer was Envestnet Asset Management, opening a new position worth an estimated $10M. The largest seller was Bank of America, cutting an estimated $13.4M.
- 69 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2025, up from 65 in Q2 2025.
- Funds reported $132M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2025, up 13% quarter-over-quarter.
- 12 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2025 and 7 closed out, a net change of +5 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2025 was Envestnet Asset Management, an estimated $10M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2025 was Bank of America, an estimated $13.4M sold.
Based on aggregated 13F filings for Q3 2025.